Cerebrolysin side effects and risks

Reported side effects

• Serious nonfatal harms after acute stroke: Cochrane: 20/667 (3.0%) versus 8/668 (1.2%); RR 2.39, 95% CI 1.10–5.23., serious (source)
• Headache: CARS 1: 6/104 (5.8%) versus 3/104 (2.9%) placebo., mild (source)
• Insomnia: CARS 1: 6/104 (5.8%) versus 4/104 (3.8%) placebo., moderate (source)
• Severe allergy or shock: Austrian label: <1/10,000; a life threatening case is published., serious. Stop administration and get emergency care. (source)
• Seizure: Austrian label: <1/10,000. A TBI cohort reported more seizures; exact rates unavailable., serious. Stop and seek urgent care for a new seizure. (source)
• Stomach upset, nausea, diarrhea or constipation: Austrian label: <1/10,000. Label rates differ from all cause trial event rates., mild (source)
• Agitation, confusion or poor sleep: Austrian label: 1/10,000 to <1/1,000., moderate (source)
• Warmth, sweating, itching or dizziness: Austrian label: 1/10,000 to <1/1,000; rapid administration can contribute., mild (source)
• Palpitations or irregular heartbeat: Austrian label: <1/10,000, especially with rapid administration., serious (source)
• Injection-site redness, itching or burning: Austrian label: <1/10,000; community injection pain rates are unknown., mild (source)
• Brain fog, mood changes or flu-like feelings: Community reports; no reliable rate or proven cause., moderate (source)

Stop and get help if

• Trouble breathing, swollen lips or tongue, collapse or widespread hives: Stop administration and call emergency services now.
• New seizure, repeated seizures or not waking normally: Get emergency care now; protect from injury and give no further doses.
• New one-sided weakness, speech loss, sudden severe headache or reduced consciousness: Call emergency services; do not delay stroke care for a peptide dose.
• Chest pain, fainting or sustained irregular heartbeat: Stop administration and seek urgent medical assessment.
• Hot spreading injection-site redness, pus, fever or shaking chills: Seek urgent assessment for infection; retain product and batch details.

Who should avoid it

• pregnant: Human safety is unestablished. Austria allows only necessary clinical treatment.
• breastfeeding: Milk transfer and infant safety are unknown. Austria requires choosing between nursing and treatment.
• tryingToConceive: Precaution: human fertility safety and a preconception stopping interval are unknown.
• under18: Adults-only reference. Austria does not recommend use under 18 because data are insufficient.
• other: An ongoing or repeated seizure emergency is an Austrian label contraindication. Seek emergency care.
• seizureDisorder: Seizure frequency may rise. Some regional labels are stricter; review epilepsy or past post-traumatic seizures.
• other: Severe kidney impairment is an Austrian label contraindication. A safe adjusted dose is unestablished.
• kidneyDisease: Kidney severity must be checked; severe impairment is contraindicated.
• other: Prior hypersensitivity is contraindicated; life-threatening anaphylaxis has been reported.
• other: The Austrian label advises caution with an allergic tendency.
• activeCancer: Precaution: an Alzheimer trial reported IGF-I changes. Active-cancer safety is unknown; this is not a label contraindication.
• heartCondition: Rapid administration can cause palpitations or rhythm changes; review before exposure.
• uncontrolledBloodPressure: High-dose MAO inhibitors with 30–40 mL Cerebrolysin can raise blood pressure.
• psychiatricCondition: Agitation, confusion and insomnia are reported. Unstable mood conditions need review.
• bleedingDisorder: Muscle injection may cause bleeding or a hematoma; assess the route and bleeding risk.
• testedAthlete: No named WADA ruling found. IV volume rules apply even when a drug is not named.

Interactions

• MAO inhibitors: Additive effects; high-dose MAO inhibitors with 30–40 mL Cerebrolysin can raise blood pressure.
• Other antidepressants: Austria warns of additive effects and suggests clinician-led antidepressant dose review. Do not change antidepressants independently.
• Balanced amino-acid infusions: Do not mix in the same infusion; the Austrian label identifies an incompatibility.
• Lipid infusions or same-syringe medicines: Lipid-containing or pH-changing solutions are incompatible. Vitamins and heart medicines should not share the same syringe.
• Blood thinners and antiplatelet drugs: Muscle injections may cause bleeding or bruising. This is a route precaution, not a proven Cerebrolysin drug interaction.
• Donepezil: A randomized combination trial found no significant added cognitive benefit; clinician-managed use was studied.
• Other neuroactive peptide mixtures: Self-use combinations lack controlled human safety evidence. Other brain-derived preparations are not interchangeable.

Product quality risks

• One chemical study identified 638 peptides in an online sample. It did not establish sterility, dose consistency or market-wide authenticity.
• A lab comparison found other mixtures had different composition and activity. It was not a counterfeit-prevalence survey.
• Unregulated injections may be mislabeled, contaminated or nonsterile. No representative Cerebrolysin online-market purity survey was found.
• A powder sold under this name is not established as equivalent to the licensed liquid.